Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?

Illumina is expanding its AI strategy around biological data generated by its sequencing platforms, including the Billion Cell Atlas initiative and broader drugmaker partnerships. The company’s improving core business and potential to monetize its scientific data could create a new growth engine, although execution on translating these capabilities into commercial value remains the key uncertainty.